---
title: "輝瑞股票的深度下跌引發了關於其長期價值的爭論"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/288182651.md"
description: "輝瑞的股票自 2021 年高峰以來已下跌超過 50%，原因是專利到期和 COVID 產品銷售下降。分析師的情緒分歧，大多數人持謹慎態度，而一些人則將此次下跌視為逆勢買入的機會。該公司繼續推進其在疫苗、腫瘤學和偏頭痛治療方面的研發管線，並在終止內部項目後收購了一項 GLP-1 候選藥物"
datetime: "2026-05-31T21:01:07.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/288182651.md)
  - [en](https://longbridge.com/en/news/288182651.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/288182651.md)
---

# 輝瑞股票的深度下跌引發了關於其長期價值的爭論

Stock under pressure: Pfizer shares are down over 50% from 2021 highs, weighed by patent risks and COVID product declines. Investor sentiment split: Most analysts rate the stock cautiously, but some see the sell-off as a contrarian buying opportunity. Pipeline in focus: Pfizer is advancing vaccines, oncology, and migraine drugs, and acquired a GLP-1 candidate after ending its own program.

### 相關股票

- [PFE.US](https://longbridge.com/zh-HK/quote/PFE.US.md)
- [BBH.US](https://longbridge.com/zh-HK/quote/BBH.US.md)
- [PBE.US](https://longbridge.com/zh-HK/quote/PBE.US.md)
- [FBT.US](https://longbridge.com/zh-HK/quote/FBT.US.md)
- [IHE.US](https://longbridge.com/zh-HK/quote/IHE.US.md)
- [LABU.US](https://longbridge.com/zh-HK/quote/LABU.US.md)
- [IBB.US](https://longbridge.com/zh-HK/quote/IBB.US.md)
- [VHT.US](https://longbridge.com/zh-HK/quote/VHT.US.md)
- [BIB.US](https://longbridge.com/zh-HK/quote/BIB.US.md)
- [XBI.US](https://longbridge.com/zh-HK/quote/XBI.US.md)
- [IBBQ.US](https://longbridge.com/zh-HK/quote/IBBQ.US.md)
- [LABD.US](https://longbridge.com/zh-HK/quote/LABD.US.md)
- [SBIO.US](https://longbridge.com/zh-HK/quote/SBIO.US.md)
- [IXJ.US](https://longbridge.com/zh-HK/quote/IXJ.US.md)
- [ARKG.US](https://longbridge.com/zh-HK/quote/ARKG.US.md)
- [XLV.US](https://longbridge.com/zh-HK/quote/XLV.US.md)

## 相關資訊與研究

- [健喬營收／5 月營收 6 億元 年月雙增、寫歷史次高](https://longbridge.com/zh-HK/news/289304258.md)
- [FDA 準輝瑞公司一款用於治療兒童出血性疾病的藥物](https://longbridge.com/zh-HK/news/289106966.md)
- [規避科技股劇烈波動，精選 8 只穩健標的個股](https://longbridge.com/zh-HK/news/289277399.md)
- [Cerity Partners LLC 購買了輝瑞公司 1,448,806 股股票](https://longbridge.com/zh-HK/news/289292675.md)
- [輝瑞的 Hympavzi 獲得 FDA 批准擴展適應症，用於治療血友病](https://longbridge.com/zh-HK/news/289169446.md)